Identification of CD56dim subpopulation marked with high expression of GZMB/PRF1/PI‐9 in CD56+ interferon‐α‐induced dendritic cells
- 4 March 2021
- journal article
- research article
- Published by Wiley in Genes to Cells
- Vol. 26 (5) , 313-327
Abstract
As the sentinels of innate and adaptive immune system, dendritic cells (DCs) have been considered to hold a great promise for medical application. Among the diverse types of DCs, monocyte‐derived DCs (mo‐DCs) generated in vitro have been most commonly employed. We have been improving the culture protocol and devised a protocol to produce mature interferon‐α‐induced DCs (IFN‐DCs), hereinafter called (mat)IFN‐DCs. While exploring the relationship between the expression of CD56 and the cytotoxic activity of (mat)IFN‐DCs, we unexpectedly found that sorting of (mat)IFN‐DCs with CD56 antibody‐coated microbeads (MB) resulted in fractionating cells with tumoricidal activity into the flow‐through (FT) but not MB‐bound fraction. We uncovered that the FT fraction contains cells expressing low but substantial level of CD56. Moreover, those cells express granzyme B (GrB), perforin (PFN), and serpin B9 at high levels. By employing a specific inhibitor of PFN, we confirmed that direct tumoricidal activity relies on the GrB/PFN pathway. We designated subpopulation in FT fraction as CD56dim and that in CD56 positively sorted fraction as CD56bright, respectively. This is the first time, to our knowledge, to identify subpopulations of CD56‐positive IFN‐DCs with distinct tumoricidal activity which is ascribed to high expression of the components of GrB/PFN pathway.Keywords
This publication has 56 references indexed in Scilit:
- CD56 marks human dendritic cell subsets with cytotoxic potentialOncoImmunology, 2013
- Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal PotentialPLOS ONE, 2012
- Increased numbers of tumor-lysing monocytes in cancer patientsMolecular and Cellular Endocrinology, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Harnessing Human Dendritic Cell Subsets to Design Novel VaccinesAnnals of the New York Academy of Sciences, 2009
- CD56bright natural killer (NK) cells: an important NK cell subsetImmunology, 2009
- Monocyte derived dendritic cells generated by IFN-α acquire mature dendritic and natural killer cell properties as shown by gene expression analysisJournal of Translational Medicine, 2007
- Activation-Induced Expression of CD56 by T Cells Is Associated With a Reprogramming of Cytolytic Activity and Cytokine Secretion Profile In VitroHuman Immunology, 2006
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994